T1	Parsing_Error 0 2	1.
T2	Parsing_Error 191 193	2.
T3	Parsing_Error 294 296	3.
T4	Parsing_Error 468 470	4.
T5	Parsing_Error 558 560	5.
T6	Parsing_Error 591 593	6.
T7	Parsing_Error 769 771	7.
T8	Parsing_Error 875 877	8.
T9	Parsing_Error 899 901	9.
T10	Parsing_Error 935 938	10.
T11	Parsing_Error 978 981	11.
T12	Parsing_Error 1053 1056	12.
T13	Condition 16 31	post-menopausal
T14	Person 32 37	woman
T15	Temporal 58 80	six (6) months or more
T16	Temporal 82 118	immediately prior to screening visit
T17	Condition 130 146	menstrual period
T18	Negation 120 127	without
R1	Has_negation Arg1:T17 Arg2:T18	
R2	AND Arg1:T15 Arg2:T17	
R3	Has_temporal Arg1:T15 Arg2:T16	
T19	Procedure 157 169	hysterectomy
T20	Temporal 151 156	prior
R4	Has_temporal Arg1:T19 Arg2:T20	
T21	Procedure 177 189	oophorectomy
*	OR T19 T17 T21
T22	Condition 205 213	pregnant
T23	Condition 217 226	lactating
*	OR T23 T22
T24	Non-query-able 230 292	is attempting or expecting to become pregnant during the study
T25	Post-eligibility 230 292	is attempting or expecting to become pregnant during the study
T26	Person 297 302	Women
T27	Measurement 324 337	liver enzymes
T28	Condition 341 354	liver disease
T29	Value 319 323	high
R5	Has_value Arg1:T27 Arg2:T29	
*	OR T27 T28
T30	Measurement 357 360	ALT
T31	Measurement 364 367	AST
T32	Value 368 387	exceeding 2.0 x ULN
*	OR T31 T30
T33	Scope 357 367	ALT or AST
R6	Has_value Arg1:T33 Arg2:T32	
T34	Measurement 392 407	total bilirubin
T35	Value 408 427	exceeding 1.5 x ULN
R7	Has_value Arg1:T34 Arg2:T35	
T36	Temporal 428 440	at screening
T37	Reference_point 431 440	screening
R8	Has_index Arg1:T36 Arg2:T37	
R9	Has_temporal Arg1:T34 Arg2:T36	
R10	Has_temporal Arg1:T33 Arg2:T36	
T38	Temporal 504 541	in the 30 days prior to the screening
T39	Reference_point 528 541	the screening
R11	Has_index Arg1:T38 Arg2:T39	
T40	Drug 483 503	investigational drug
R12	Has_temporal Arg1:T40 Arg2:T38	
T41	Person 561 566	Women
T42	Condition 585 589	PCOS
T43	Observation 574 581	history
R13	Has_temporal Arg1:T42 Arg2:T43	
T44	Drug 616 628	testosterone
T45	Drug 630 639	progestin
T46	Drug 641 649	androgen
T47	Drug 651 659	estrogen
T48	Drug 661 678	anabolic steroids
T49	Drug 680 684	DHEA
T50	Temporal 706 745	for at least 2 weeks prior to screening
T51	Temporal 750 766	during the study
T52	Reference_point 736 745	screening
R14	Has_index Arg1:T50 Arg2:T52	
T53	Drug 688 705	hormonal products
T54	Undefined_semantics 688 705	hormonal products
*	OR T53 T49 T48 T47 T46 T45 T44
T55	Scope 616 705	testosterone, progestin, androgen, estrogen, anabolic steroids, DHEA or hormonal products
R15	Has_temporal Arg1:T55 Arg2:T50	
R16	Has_temporal Arg1:T55 Arg2:T51	
T56	Drug 779 798	oral contraceptives
T57	Temporal 799 823	in the preceding 2 weeks
R17	Has_temporal Arg1:T56 Arg2:T57	
T58	Drug 832 845	Depo-ProveraÂ®
T59	Temporal 846 872	in the preceding 10 months
R18	Has_temporal Arg1:T58 Arg2:T59	
T60	Device 885 888	IUD
T61	Person 902 907	Women
T62	Drug 924 933	narcotics
T63	Person 939 944	Women
T64	Drug 962 976	spironolactone
T65	Condition 1024 1027	HIV
T66	Condition 1031 1042	Hepatitis A
T67	Condition 1031 1040;1044 1045	Hepatitis B
T68	Condition 1031 1040;1049 1050	Hepatitis C
*	OR T68 T67 T66 T65
T69	Non-query-able 1057 1323	Clinically significant abnormal findings on screening examination or any condition which in the opinion of the investigator would interfere with the participant's ability to comply with the study instructions or endanger the participant if she took part in the study
